Skip to main content

Advertisement

SpringerLink
Log in

HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Glioblastoma multiforme (GBM) is a highly malignant brain tumor with limited therapeutic options, a high recurrence rate and mortality. Standard therapy is maximal surgical resection and radiotherapy (RT). Recent data suggest combining temozolomide with RT is better than RT alone. Adjuvant chemotherapy has a modest impact on survival. For relapsed patients there is no standard therapy, but options include chemotherapeutic agents or new agents in development. One approach to improve outcome is using targeted agents that interfere with cell-surface receptors or intracellular signaling pathways. Between 40% and 50% of GBM tumors show HER1/EGFR dysregulation, and almost half co-express the constitutively active mutant receptor subtype EGFRvIII, which may contribute to the aggressive and refractory course of GBM. Numerous studies show a relationship between aberrant HER1/EGFR biology and tumorigenicity in GBM cells. Two available HER1/EGFR tyrosine kinase inhibitors (TKIs) are gefitinib (Iressa®) and erlotinib (Tarceva™); both show antitumor and radiosensitization effects in vitro and in animal models of GBM. Clinical trials in patients with GBM and other gliomas are ongoing. Preliminary and published results from trials of gefitinib in recurrent GBM show no increased time to progression or overall survival (OS) compared with historical controls. Studies with erlotinib show greater antitumor activity in patients with GBM than with gefitinib, although the impact of both agents on OS remains unclear. GBM treatment with HER1/EGFR TKIs alone or combined with other targeted therapies and conventional modalities deserve further investigation and refinement, as does our understanding of their mechanisms of action and the role of genetics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 1995–1999. Central Brain Tumor Registry of the United States, 2002

  2. P Kleihues PC Burger BW Scheithauer et al. (1993) Histological Typing of Tumours of the Central Nervous System EditionNumber2 Springer-Verlag Berlin

    Google Scholar 

  3. MD Prados V Levin (2000) ArticleTitleBiology and treatment of malignant glioma Semin Oncol 27 IssueIDSuppl 6 1–10

    Google Scholar 

  4. HS Friedman T Kerby H Calvert (2000) ArticleTitleTemozolomide and treatment of malignant glioma Clin Cancer Res 6 2585–2597

    Google Scholar 

  5. DR Macdonald (2001) ArticleTitleTemozolomide for recurrent high-grade glioma Semin Oncol 28 3–12 Occurrence Handle10.1053/sonc.2001.26648

    Article  Google Scholar 

  6. R Stupp WP Mason MJ Bent ParticleVan Den et al. (2004) ArticleTitleConcomitant and adjuvant temozolomide (TMZ) and radiotherapy for newly diagnosed glioblastoma multiforme (GBM) Conclusive results of a randomized phase III trials by the EORTC brain and RT groups and NCIC clinical trials group. Proc Am Soc Clin Oncol 23 1

    Google Scholar 

  7. DC Shrieve E Alexander SuffixIII PM Black et al. (1999) ArticleTitleTreatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome J Neurosurg 90 72–77 Occurrence Handle10413158

    PubMed  Google Scholar 

  8. HA Fine KBG Dear JS Loeffler et al. (1993) ArticleTitleMeta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 71 2585–2597 Occurrence Handle8453582

    PubMed  Google Scholar 

  9. LA Stewart (2002) ArticleTitleChemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials The Lancet 359 1011–1018 Occurrence Handle10.1016/S0140-6736(02)08091-1

    Article  Google Scholar 

  10. LM DeAngelis (2003) ArticleTitleBenefits of adjuvant chemotherapy in high-grade gliomas Semin Oncol 30 15–18

    Google Scholar 

  11. M Westphal DC Hilt E Bortley et al. (2003) ArticleTitleA phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro-Oncol 5 79–88 Occurrence Handle10.1215/S1522851702000236 Occurrence Handle12672279

    Article  PubMed  Google Scholar 

  12. H Brem S Piantadosi PC Burger et al. (1995) ArticleTitlePlacebo–controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas The Polymer-brain Tumor Treatment Group. The Lancet 345 1008–1012

    Google Scholar 

  13. WK Yung RE Albright J Olson et al. (2000) ArticleTitleA phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 588–593

    Google Scholar 

  14. Levin V, Yung A, Prados M et al.: Phase II study of Temodal (temozolomide) at first relapse in anaplastic astrocytoma (AA) patients. Proc Am Soc Clin Oncol: (abstract 1370), 1997

  15. BE Lally J Lacy JM Piepmeier et al. (1997) ArticleTitleSurvival analysis for patients with primary brain tumors treated with temozolomide Proc Am Soc Clin Oncol 22 113

    Google Scholar 

  16. AA Brandes M Ermani U Basso et al. (2002) ArticleTitleTemozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study Oncology 63 38–41 Occurrence Handle10.1159/000065718 Occurrence Handle12187069

    Article  PubMed  Google Scholar 

  17. KA Jaeckle KR Hess A Yung et al. (2003) ArticleTitlePhase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a north american brain tumor consortium study J Clin Oncol 21 2305–2311 Occurrence Handle10.1200/JCO.2003.12.097 Occurrence Handle12805331

    Article  PubMed  Google Scholar 

  18. MR Gilbert P Wen F Lieberman et al. (2003) ArticleTitlePhase I/II study of combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: a north american brain tumor consortium (NABTC) study Proc Am Soc Clin Oncol 22 113

    Google Scholar 

  19. ET Wong KR Hess MJ Gleason et al. (1999) ArticleTitleOutcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 2572–2578 Occurrence Handle10561324

    PubMed  Google Scholar 

  20. CL Arteaga (2001) ArticleTitleThe epidermal growth factor receptor: from mutant oncogene in non human cancers to therapeutic target in human neoplasia J Clin Oncol 19 IssueIDSuppl 1 32S–40S Occurrence Handle11560969

    PubMed  Google Scholar 

  21. HH Sedlacek (2000) ArticleTitleKinase inhibitors in cancer therapy A look ahead. Drugs 59 435–476

    Google Scholar 

  22. A Wells (1999) ArticleTitleMolecules in focus. EGFR receptor Int J Biochem Cell Biol 31 637–643 Occurrence Handle10.1016/S1357-2725(99)00015-1 Occurrence Handle10404636

    Article  PubMed  Google Scholar 

  23. C Arteaga (2003) ArticleTitleTargeting HER1/EGFR: a molecular approach to cancer therapy Sem Oncol 30 IssueID(Suppl 7 3–14 Occurrence Handle10.1016/S0093-7754(03)00185-4

    Article  Google Scholar 

  24. Shepherd FA, Pereira J, Ciuleanu TE et al.: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A national cancer institute of Canada clinical trials group (NCIC CTG) trial. Presented at Am Soc Clin Oncol: (abstract 7022), 2004

  25. DS Salomon R Brandt F Ciardiello N Normanno (1995) ArticleTitleEpidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 183–232 Occurrence Handle7612182

    PubMed  Google Scholar 

  26. P Tang PA Steck WK Yung (1997) ArticleTitleThe autocrine loop of TGF-alpha/EGFR and brain tumors J Neurooncol 35 303–314 Occurrence Handle10.1023/A:1005824802617 Occurrence Handle9440027

    Article  PubMed  Google Scholar 

  27. CY Thomas M Chouinard M Cox et al. (2003) ArticleTitleSpontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells Int J Cancer 104 19–27 Occurrence Handle10.1002/ijc.10880 Occurrence Handle12532415

    Article  PubMed  Google Scholar 

  28. M Lund-Johansen R Bjerkvig PA Humphrey SH Bigner DD Bigner OD Laerum (1990) ArticleTitleEffect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro Cancer Res 50 6039–6044 Occurrence Handle2393868

    PubMed  Google Scholar 

  29. M-E Halatsch E Gehrke F A-Borhani et al. (2002) ArticleTitleEGFR but not PDGFR-β expression correlates to the antiproliferative effect of growth factor withdrawal in glioblastoma multiforme cell lines Anticancer Res 23 2315–2320

    Google Scholar 

  30. N Shinojima K Tada S Shiraishi et al. (2003) ArticleTitlePrognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme Cancer Res 63 6962–6970 Occurrence Handle14583498

    PubMed  Google Scholar 

  31. A Chakravarti A Chakladar MA Delaney DE Latham JS Loeffler (2002) ArticleTitleThe epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner Cancer Res 62 4307–4315 Occurrence Handle12154034

    PubMed  Google Scholar 

  32. FG Barker ML Simmons SM Chang et al. (2001) ArticleTitleEGFR overexpression and radiation response in glioblastoma multiforme Int J Radiation Oncology Biol Phys 2001 IssueID51 410–418 Occurrence Handle10.1016/S0360-3016(01)01609-1

    Article  Google Scholar 

  33. CT Chu KD Everiss CJ Wilkstrand et al. (1997) ArticleTitleReceptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor (EGFRvIII) Biochem J 324 855–861 Occurrence Handle9210410

    PubMed  Google Scholar 

  34. CJ Wilkstrand LP Hale SK Batra et al. (1995) ArticleTitleMonoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas Cancer Res 55 3140–3148 Occurrence Handle7606735

    PubMed  Google Scholar 

  35. DK Moscatello M Holgado-Madruga AK Godwin et al. (1995) ArticleTitleFrequent expression of a mutant epidermal growth factor receptor in multiple human tumors Cancer Res 55 5536–5539 Occurrence Handle7585629

    PubMed  Google Scholar 

  36. R Nishikawa XD Ji RC Harmon et al. (1994) ArticleTitleA mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity Proc Natl Acad Sci USA 91 7727–7731 Occurrence Handle8052651

    PubMed  Google Scholar 

  37. R Nishikawa XD Ji RC Harmon et al. (1994) ArticleTitleA mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity Proc Natl Acad Sci USA 91 7727–7731 Occurrence Handle8052651

    PubMed  Google Scholar 

  38. M Nagane F Coufal H Lin O Bogler WK Cavenee HJ Huang (1996) ArticleTitleA common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis Cancer Res 56 5079–5086 Occurrence Handle8895767

    PubMed  Google Scholar 

  39. Q Wei B Qian L Clarke et al. (2004) ArticleTitleMutant epidermal growth factor receptor (EGFRvIII) potentiates development of gilomas in a transgenic mouse models Proc Am Assoc Cancer Res 45 5085

    Google Scholar 

  40. DK Moscatello M Holgado-Madruga DR Emlet et al. (1998) ArticleTitleConstitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor J Biol Chem 273 200–206 Occurrence Handle10.1074/jbc.273.1.200 Occurrence Handle9417065

    Article  PubMed  Google Scholar 

  41. Y Narita M Nagane K Mishima HJ Huang FB Furnari WK Cavenee (2002) ArticleTitleMutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas Cancer Res 62 6764–6769 Occurrence Handle12438278

    PubMed  Google Scholar 

  42. SA Prigent M Nagane H Lin et al. (1996) ArticleTitleEnhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway J Biol Chem 271 25639–25645 Occurrence Handle10.1074/jbc.271.41.25639 Occurrence Handle8810340

    Article  PubMed  Google Scholar 

  43. M Klingler-Hoffmann P Bukczynska T Tiganis (2003) ArticleTitleInhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells Int J Cancer 105 331–339 Occurrence Handle10.1002/ijc.11085 Occurrence Handle12704666

    Article  PubMed  Google Scholar 

  44. G Choe S Horvath TF Cloughesy et al. (2003) ArticleTitleAnalysis of the phosphatidylinositol 3’-kinase signaling pathway in glioblastoma patients in vivo Cancer Res 63 2742–2746 Occurrence Handle12782577

    PubMed  Google Scholar 

  45. M Klingler-Hoffmann MT Fodero-Tavoletti K Mishima et al. (2001) ArticleTitleThe protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor J Biol Chem 276 46313–46318 Occurrence Handle10.1074/jbc.M106571200 Occurrence Handle11514572

    Article  PubMed  Google Scholar 

  46. H-JS Huang M Nagane CK Klingbeil et al. (1997) ArticleTitleThe enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signalling J Biol Chem 272 2927–2935 Occurrence Handle10.1074/jbc.272.5.2927 Occurrence Handle9006938

    Article  PubMed  Google Scholar 

  47. Guillamo J-S, Leuraud P, de Bouard S et al.: Anti-proliferative and anti-invasive EGFR amplification dependent and anti-angiogenic EGFR independent activity of ZD1839 (‘Iressa’) tyrosine kinase inhibitor on human glioblastomas. Proc Am Assoc Cancer Res 44: (abstract 1009), 2003

  48. Learn CA, Archer GE, Riggins GJ et al.: Inhibition of cell cycle progression and invasion of cells expressing epidermal growth factor receptor (EGFR) but not mutant EGFR variant III (EGFRvIII) by the specific EGFR tyrosine kinase inhibitor (TKI) gefitinib (Iressa, ZD1839). Proc Am Assoc Cancer Res 44: (abstract 6199), 2003

  49. Li B, Chang C-M, Yuan M et al.: Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Society for neuro-oncology eighth annual meeting: 291(abstract CB-13), 2003

  50. B Stea R Falsey K Kislin et al. (2003) ArticleTitleTime and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 (’Iressa’) Cancer Lett 202 43–51 Occurrence Handle10.1016/j.canlet.2003.07.006 Occurrence Handle14643025

    Article  PubMed  Google Scholar 

  51. Stea B, Kislin K, Stadheim CR et al.: ZD1839 (Iressa) radiosensitizes glioblastoma multiforme by altering patterns of gene expression in a time dependent manner. Proc Am Assoc Cancer Res 44: (abstract 6018), 2003

  52. JD Moyer EG Barbacci KK Iwata et al. (1997) ArticleTitleInduction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 57 4838–4848 Occurrence Handle9354447

    PubMed  Google Scholar 

  53. VA Pollack DM Savage DA Baker et al. (1999) ArticleTitleInhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice J Pharmacol Exp Ther 291 739–748 Occurrence Handle10525095

    PubMed  Google Scholar 

  54. P Chinnaiyan S-M Huang E Armstrong PM Harari (2003) ArticleTitleRadiosensitization following EGFR signaling inhibition by erlotonib (Tarceva™) Int J Radiat Oncol Biol Phys 57 IssueID2 Suppl S294 Occurrence Handle10.1016/S0360-3016(03)01153-2

    Article  Google Scholar 

  55. Carlson BL, Schroeder MA, Mladek AC et al.: Radiosensitization by OSI-774 of serially transplantable human GBM xenografts. Society for neuro-oncology eighth annual Meeting: 321(abstract MO-01), 2003

  56. Halatsch M-E, Gehrke E, A-Borhani F et al.: Inverse correlation of epidermal growth factor receptor (EGFR) messenger RNA induction and suppression of in vitro tumorigenicity by OSI-774, an EGFR tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. Proc Am Assoc Cancer Res 44: (abstract 4683), 2003

  57. JN Rich DA Reardon T Peery et al. (2004) ArticleTitlePhase II trial of gefitinib in recurrent glioblastoma J Clin Oncol 22 133–142 Occurrence Handle10.1200/JCO.2004.08.110 Occurrence Handle14638850

    Article  PubMed  Google Scholar 

  58. MD Prados S Chang E Burton et al. (2003) ArticleTitlePhase I study of OSI-774 alone or with temozolomide in patients with malignant glioma Eur J Cancer Suppls 1 S14 Occurrence Handle10.1016/S1359-6349(03)90067-X

    Article  Google Scholar 

  59. KK Iwata K Provoncha N Gibson (2002) ArticleTitleInhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva) Proc Am Soc Clin Oncol 21 21a

    Google Scholar 

  60. Vogelbaum MA, Goldlust S, Kanner A: The EGFR tyrosine kinase inhibitor Tarceva™ (OSI-774) shows activity against both wild-type and mutant EGFR function. Society for neuro-oncology eighth annual meeting: 309 (abstract ET-47), 2003

  61. A Lal CA Glazer HM Martinson et al. (2002) ArticleTitleMutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion Cancer Res 62 3335–3339 Occurrence Handle12067969

    PubMed  Google Scholar 

  62. AB Heimberger CA Learn GE Archer et al. (2002) ArticleTitleBrain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa) Clin Cancer Res 8 3496–3502

    Google Scholar 

  63. Allen AM, Ethier SP: CI-1033 a pan Erb-B family tyrosine kinase inhibitor induces apoptosis in glioblastoma cells in a non-growth arrest pattern. Proc Am Assoc Cancer Res 44: (abstract 4683), 2003

  64. JL Eller SL Longo DJ Hicklin et al. (2002) ArticleTitleActivity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme Neurosurgery 51 1005–1013 Occurrence Handle10.1097/00006123-200210000-00028

    Article  Google Scholar 

  65. TG Johns E Stockert G Ritter et al. (2002) ArticleTitleNovel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene Int J Cancer 98 398–408 Occurrence Handle10.1002/ijc.10189 Occurrence Handle11920591

    Article  PubMed  Google Scholar 

  66. S Takasu T Takahashi S Okamoto et al. (2003) ArticleTitleRadioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor J Neurooncol 63 247–256 Occurrence Handle10.1023/A:1024320516341 Occurrence Handle12892230

    Article  PubMed  Google Scholar 

  67. KA Cohen T Liu R Bissonette et al. (2003) ArticleTitleDAB389EGF fusion protein therapy of refractory glioblastoma multiforme Curr Pharm Biotechnol 4 39–49 Occurrence Handle10.2174/1389201033378039 Occurrence Handle12570681

    Article  PubMed  Google Scholar 

  68. A Yung Vredenburgh T Cloughesy et al. (2004) ArticleTitleErlotinib HCl for glioblastoma multiforme in first relapse, a phase II trial Proc Am Soc Clin Oncol 23 120

    Google Scholar 

  69. MA Vogelbaum D Peereboom G Stevens et al. (2004) ArticleTitlePhase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results Proc Am Soc Clin Oncol 23 121

    Google Scholar 

  70. JJ Raizer LE Abrey P Wen et al. (2004) ArticleTitleA phase II trial of erlotinib (OSI-774) in patients (Pts) with recurrent malignant gliomas (MG) not on EIAEDs Proc Am Soc Clin Oncol 23 107

    Google Scholar 

  71. JH Uhm KV Ballman C Giannini et al. (2004) ArticleTitlePhase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma Proc Am Soc Clin Oncol 23 108

    Google Scholar 

  72. FS Lieberman T Cloughesy H Fine et al. (2004) ArticleTitleNABTC phase I-II study of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas Proc Am Soc Clin Oncol 23 109

    Google Scholar 

  73. A Chakravarti W Seiferheld HI Robins et al. (2004) ArticleTitleAn update of phase I data from RTOG 0211: A phase I/II clinical study of gefitinib + radiation for newly-diagnosed glioblastoma (GBM) patients Proc Am Soc Clin Oncol 23 124

    Google Scholar 

  74. M Prados W Yung P Wen et al. (2004) ArticleTitlePhase I study of ZD1839 plus temozolomide in patients with malignant glioma A study of the north american brain tumor consortium. Proc Am Soc Clin Oncol 23 108

    Google Scholar 

  75. ET Wong KR Hess MJ Gleason et al. (1999) ArticleTitleOutcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 2572–2578 Occurrence Handle10561324

    PubMed  Google Scholar 

  76. GM Clark R Perez-Soler L Siu et al. (2003) ArticleTitleRash severity is predictive of increased survival with erlotinib HCl Proc Am Soc Clin Oncol 22 196

    Google Scholar 

  77. L Saltz M Kies JL Abbruzzese et al. (2003) ArticleTitleThe presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies Proc Am Soc Clin Oncol 22 204

    Google Scholar 

  78. J Albanell F Rojo S Averbuch et al. (2002) ArticleTitlePharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Clin Oncol 20 110–124 Occurrence Handle10.1200/JCO.20.1.110 Occurrence Handle11773160

    Article  PubMed  Google Scholar 

  79. SN Malik LL Siu EK Rowinsky et al. (2003) ArticleTitlePharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients Clin Cancer Res 9 2478–2486

    Google Scholar 

  80. N Finkler A Gordon M Crozier et al. (2001) ArticleTitlePhase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma Proc Am Soc Clin Oncol 20 208a

    Google Scholar 

  81. GN Hortobagyi G Sauter (2003) ArticleTitleChallenges and opportunities for erlotinib (Tarceva): what does the future hold Semin Oncol 30 IssueIDSuppl 7 47–53 Occurrence Handle10.1016/S0093-7754(03)00188-X

    Article  Google Scholar 

  82. L Frederick X-Y Wang G Eley et al. (2000) ArticleTitleDiversity and frequency of epidermal growth factor receptor mutations in human glioblastomas Cancer Res 60 1383–1387 Occurrence Handle10728703

    PubMed  Google Scholar 

  83. W Pao v Miller M Zakowski et al. (2004) ArticleTitleEGFR receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of gefitinib and erlotinib Proc Natl Acad Sci USA 101 13306–13311 Occurrence Handle10.1073/pnas.0405220101 Occurrence Handle15329413

    Article  PubMed  Google Scholar 

  84. TJ Lynch DW Bell R Sordella et al. (2004) ArticleTitleActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib New Engl J Med 350 2129–2139 Occurrence Handle10.1056/NEJMoa040938 Occurrence Handle15118073

    Article  PubMed  Google Scholar 

  85. JG Paez PA Janne JC Lee et al. (2004) ArticleTitleEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497–1500 Occurrence Handle10.1126/science.1099314 Occurrence Handle15118125

    Article  PubMed  Google Scholar 

  86. PS Mischel R Shai T Shi et al. (2003) ArticleTitleIdentification of molecular subtypes of glioblastoma by gene expression profiling Oncogene 22 2361–2373 Occurrence Handle10.1038/sj.onc.1206344 Occurrence Handle12700671

    Article  PubMed  Google Scholar 

  87. AM Stark P Witzel RJ Strege HH Hugo HM Mehdorn (2003) ArticleTitlep53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme J Neurol Neurosurg Psychiatry 74 779–783 Occurrence Handle10.1136/jnnp.74.6.779 Occurrence Handle12754350

    Article  PubMed  Google Scholar 

  88. G Lammering K Valerie P-S Lin et al. (2001) ArticleTitleRadiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor Clin Cancer Res 7 682–690

    Google Scholar 

  89. G Bowers D Reardon T Hewitt et al. (2001) ArticleTitleThe relative role of ErbB1-4 receptor kinases in radiation signal transduction responses of human carcinoma cells Oncogene 20 1388–1397 Occurrence Handle10.1038/sj.onc.1204255 Occurrence Handle11313882

    Article  PubMed  Google Scholar 

  90. IB Weinstein (2002) ArticleTitleAddiction to oncogenes – the achilles heal of cancer Science 297 63–64 Occurrence Handle10.1126/science.1073096 Occurrence Handle12098689

    Article  PubMed  Google Scholar 

  91. Q-W Fan KM Specht C Zhang DD Goldenberg KM Shokat WA Weiss (2003) ArticleTitleCombinatorial efficacy achieved through two-point blockade within a signaling pathway – a chemical genetic approach Cancer Res 63 8930–8938 Occurrence Handle14695210

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Feinberg School of Medicine, Northwestern University, Abbott Hall, Room 1123, 710 North Lake Shore Drive, Chicago, IL, 60611, USA

    Jeffrey J. Raizer

Authors
  1. Jeffrey J. Raizer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey J. Raizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raizer, J.J. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 74, 77–86 (2005). https://doi.org/10.1007/s11060-005-0603-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-005-0603-7

Keywords

Search

Navigation